Precision Biotherapeutics- mRNA Therapeutics has been identified as one of the thematic sectors under the BioE3 Policy for ‘fostering high-performance biomanufacturing’.
mRNA therapy can potentially transform existing therapies or target difficult indications, including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer. mRNA technology can be used for the following therapeutic applications:
There are many benefits of mRNA therapies as compared to similar emerging platforms, such as modular nature with easy to-switch sequences for specifically targeting different proteins or genes, the potential to directly affect the underlying cause of a disease faster manufacturing times compared to antibodies or protein-based drugs, predictable pharmacokinetics, and lack of genome integration.
Recognizing the fact that mRNA therapies represent an emerging precision medicine field with great promise for preventing and treating human diseases DBT and BIRAC invites proposals on ‘Precision Biotherapeutics-mRNA therapeutics ‘under the Bio E3 policy to further the indigenous development and manufacturing of this important biotherapeutic.
The proposals will be invited under 2 categories
For more details please see the call document
Proposals for the Scheme is required to be submitted online only. To submit a proposal online, please log on to the BIRAC website (www.birac.nic.in).
No Hard Copy to be submitted. Proposals submitted online only would be considered.
Last date for Submission of Proposals: 31st May 2025 (midnight)
Details of the scheme including eligibility requirements, categories for proposal submission; guidelines for support as grant and loan; agreement templates etc. are available at www.birac.nic.in
Announcement Date: 11-04-2025
Last Submission Date: 31-05-2025